Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $18,626 | 1,215 | 87.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,375 | 4 | 11.1% |
| Gift | $188.95 | 6 | 0.9% |
| Education | $159.16 | 6 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $4,931 | 302 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $2,397 | 147 | $0 (2024) |
| NESTLE HEALTHCARE NUTRITION INC. | $2,160 | 6 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,963 | 133 | $0 (2024) |
| Janssen Biotech, Inc. | $1,840 | 111 | $0 (2024) |
| PFIZER INC. | $1,052 | 70 | $0 (2024) |
| Gilead Sciences, Inc. | $671.44 | 50 | $0 (2024) |
| Celgene Corporation | $603.14 | 45 | $0 (2024) |
| Merck Sharp & Dohme LLC | $566.52 | 40 | $0 (2024) |
| UCB, Inc. | $547.69 | 34 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,013 | 170 | ABBVIE INC. ($777.40) |
| 2023 | $2,731 | 163 | AbbVie Inc. ($656.97) |
| 2022 | $2,590 | 159 | ABBVIE INC. ($903.33) |
| 2021 | $4,860 | 177 | Nestle HealthCare Nutrition Inc. ($2,127) |
| 2020 | $2,000 | 118 | AbbVie Inc. ($481.65) |
| 2019 | $2,309 | 161 | AbbVie, Inc. ($394.37) |
| 2018 | $1,929 | 147 | AbbVie, Inc. ($402.18) |
| 2017 | $1,916 | 136 | AbbVie, Inc. ($563.82) |
All Payment Transactions
1,231 individual payment records from CMS Open Payments — Page 1 of 50
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.41 | General |
| Category: Gastroenterology | ||||||
| 12/20/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $17.69 | General |
| Category: Immunology | ||||||
| 12/18/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $19.55 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $20.56 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/06/2024 | CapsoVision, Inc. | CapsoCam Plus (Device) | Food and Beverage | Cash or cash equivalent | $15.39 | General |
| Category: Gastroenterology | ||||||
| 12/05/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $7.86 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $2.75 | General |
| 11/27/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $17.75 | General |
| Category: Immunology | ||||||
| 11/26/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $2.06 | General |
| 11/25/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $19.07 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/19/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $6.67 | General |
| Category: ENDOCRINOLOGY | ||||||
| 11/15/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $25.82 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $9.89 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/14/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $1.62 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/14/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $0.69 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/08/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $15.25 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 11/06/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: Immunology | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $21.73 | General |
| Category: Immunology | ||||||
| 11/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.60 | General |
| Category: Gastroenterology | ||||||
| 11/01/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $23.12 | General |
| Category: GI | ||||||
| 10/31/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $27.34 | General |
| Category: IMMUNOLOGY | ||||||
| 10/30/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $4.96 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/29/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $9.49 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 423 | 490 | $160,835 | $48,468 |
| 2022 | 12 | 370 | 452 | $140,296 | $41,980 |
| 2021 | 15 | 488 | 586 | $186,805 | $54,879 |
| 2020 | 16 | 480 | 621 | $172,635 | $53,486 |
All Medicare Procedures & Services
58 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 60 | 60 | $37,200 | $12,217 | 32.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 49 | 81 | $13,770 | $4,974 | 36.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 47 | 47 | $15,322 | $4,747 | 31.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 51 | 51 | $21,981 | $4,634 | 21.1% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 37 | 37 | $21,312 | $4,607 | 21.6% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 22 | 22 | $12,100 | $3,884 | 32.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 25 | 29 | $4,698 | $2,573 | 54.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 35 | 36 | $3,960 | $2,165 | 54.7% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 11 | 11 | $6,050 | $1,939 | 32.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 14 | 14 | $6,692 | $1,885 | 28.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 11 | 37 | $6,216 | $1,774 | 28.5% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 13 | 14 | $4,550 | $1,270 | 27.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 16 | 16 | $2,928 | $1,074 | 36.7% |
| 43450 | Dilation of esophagus | Facility | 2023 | 18 | 19 | $3,800 | $590.77 | 15.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 14 | 16 | $256.00 | $134.40 | 52.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 57 | 57 | $32,832 | $7,502 | 22.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 56 | 109 | $18,530 | $6,158 | 33.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 33 | 33 | $15,774 | $5,188 | 32.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 25 | 25 | $15,500 | $5,111 | 33.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 46 | 47 | $15,322 | $4,931 | 32.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 34 | 34 | $14,654 | $3,278 | 22.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 24 | 36 | $8,856 | $2,924 | 33.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 36 | 45 | $4,950 | $2,541 | 51.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 15 | 20 | $3,240 | $1,995 | 61.6% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 12 | 13 | $4,225 | $1,198 | 28.4% |
About Dr. Eldad Bialecki, M.D
Dr. Eldad Bialecki, M.D is a Gastroenterology healthcare provider based in Saint Peters, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/30/2007. The National Provider Identifier (NPI) number assigned to this provider is 1003952458.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eldad Bialecki, M.D has received a total of $21,349 in payments from pharmaceutical and medical device companies, with $3,013 received in 2024. These payments were reported across 1,231 transactions from 43 companies. The most common payment nature is "Food and Beverage" ($18,626).
As a Medicare-enrolled provider, Bialecki has provided services to 1,761 Medicare beneficiaries, totaling 2,149 services with total Medicare billing of $198,813. Data is available for 4 years (2020–2023), covering 58 distinct procedure/service records.
Practice Information
- Specialty Gastroenterology
- Location Saint Peters, MO
- Active Since 01/30/2007
- Last Updated 09/25/2025
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1003952458
Products in Payments
- ZENPEP (Drug) $2,175
- XIFAXAN (Drug) $1,749
- STELARA (Biological) $1,632
- XELJANZ (Drug) $940.63
- LINZESS (Drug) $851.94
- ENTYVIO (Biological) $822.12
- MAVYRET (Drug) $808.92
- RINVOQ (Biological) $807.84
- ZEPOSIA (Drug) $740.25
- Humira (Biological) $710.35
- HUMIRA (Biological) $699.73
- GATTEX (Drug) $575.49
- Cimzia (Drug) $547.69
- DUPIXENT (Biological) $528.17
- Linzess (Drug) $417.63
- OCALIVA (Drug) $413.09
- DIFICID (Drug) $412.28
- TRULANCE (Drug) $396.45
- Entyvio (Biological) $383.47
- Mavyret (Drug) $377.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Saint Peters
Dr. James Dimitroff, Md, MD
Gastroenterology — Payments: $20,902
Richard Geisman, M.d, M.D
Gastroenterology — Payments: $3,923
Robert Cusworth, Md, MD
Gastroenterology — Payments: $211.20
Harry Burack, Md, MD
Gastroenterology — Payments: $14.64